228 results on '"Carpenedo, Monica"'
Search Results
2. Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study
3. Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study
4. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
5. Evans syndrome: Disease awareness and clinical management in a nation‐wide ITP‐NET survey.
6. Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia
7. Characteristics of 15 Subjects Affected by IgD Multiple Myeloma and the Key Role of the Laboratory in Diagnosis: A Retrospective Study Report and Literature Review.
8. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
9. Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years
10. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
11. S298: MATERNAL AND FETAL OUTCOMES IN PREGNANCIES OF WOMEN WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER RETROSPECTIVE OBSERVATIONAL ITP-NET ITALIAN STUDY
12. PB2611: EVANS SYNDROME: DISEASE AWARENESS AND CLINICAL MANAGEMENT IN A NATION-WIDE ITALIAN SURVEY
13. S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
14. Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
15. Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
16. IgD multiple myeloma: The relevant clinical role of laboratory in the detection of rare plasma cell neoplasms
17. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
18. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis
19. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers
20. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
21. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel
22. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel
23. Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)1
24. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study
25. Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multi-Refractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists.
26. Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy.
27. Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
28. Patient preferences and willingness to pay for different options of anticoagulant therapy
29. Practical recommendations for the management of patients with ITP during the COVID-19 pandemic
30. Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation
31. Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia
32. Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
33. Attitudes to prescribing compression stockings for patients with acute dvt: the MASTER registry
34. Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation
35. A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
36. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
37. From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared?
38. IgE monoclonal gammopathy: The clinical relevance to perform the immunofixation using IgE antisera
39. Low levels of ADAMTS‐13 with high anti‐ADAMTS‐13 antibodies during remission of immune‐mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi‐institutional study
40. Quality assurance program for whole blood prothrombin time–international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation
41. Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation.
42. Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs
43. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
44. Accuracy of a Portable Prothrombin Time Monitor (Coagucheck) in Patients on Chronic Oral Anticoagulant Therapy: A Prospective Multicenter Study
45. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study
46. Clinical relevance of antiplatelet antibodies and the hepatic clearance of platelets in patients with immune thrombocytopenia
47. Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)
48. Combined Elevated Anti-Adamts-13 Antibody Level and Low Adamts-13 Activity during Remission Highly Predicts Disease Relapse in a Prospective Cohort of Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (TTP)
49. The Transition from Childhood to Adulthood in Chronic Immune Thrombocytopenia Patients: Clinical Management and the Role of Splenectomy and Thrombopoietin Receptor Agonists in a Single Center Experience
50. Clinical and Morphologic Predictors of Outcome in a Multicenter Cohort of ITP Patients Treated with Trombopoietin Analogues
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.